Announcements
- Idorsia issues invitation to the 2024 Annual General Meeting of Shareholders
- Idorsia announces changes to Idorsia Executive Committee and Board of Directors
- Idorsia announces financial results for the first quarter 2024 – advancing the company with renewed vigor
- Idorsia announces financial results for the full year of 2023 – Adapting the company to create sustainable value
- Invitation to Idorsia's Full Year 2023 and Q1 2024 Financial Reporting webcast and conference call
- Bondholders approve amended terms of the 2024 convertible bonds
- Idorsia increases the consent fee in connection with the proposed restructuring of the 2024 convertible bond
- JERAYGO (aprocitentan) recommended for approval in Europe for the treatment of resistant hypertension
- Idorsia publishes an invitation to a bondholder meeting
- Idorsia publishes a Financial Status required for an upcoming bondholder meeting
More ▼
Key statistics
SmartText not available for this item.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.00 |
---|---|
High | 0.00 |
Low | 0.00 |
Bid | -- |
Offer | -- |
Previous close | 20.10 |
Average volume | -- |
---|---|
Shares outstanding | 188.97m |
Free float | 120.68m |
P/E (TTM) | -- |
Market cap | 425.18m CHF |
EPS (TTM) | -0.3534 CHF |
Data delayed at least 15 minutes, as of Jun 28 2019.
More ▼